口服酪酸菌对肝硬化患者免疫紊乱的影响

The effects of clostridium butyricum on immuological abnonnalities in patients with hepatic cirrhosis

目的:研究口服酪酸菌对肝硬化患者细胞和体液免疫紊乱的调节作用.方法:给肝硬化患者口服酪酸菌制剂,每次一克,每日三次,共三个月.治疗期间禁用任何抗菌药物及影响免疫的药物,检测治疗前后周围静脉血之CD3,CD4,CD8,NK及免疫球蛋白A,G,M.结果:治疗三个月后血浆免疫球蛋白G和A的水平明显降低(P<0.05).结论:口服酪酸菌可通过抑制肠道有害菌群过度生长,减少有害抗原进入人体循环,从而改善肝硬化患者体液免疫紊乱状态.

Aims: To evaluate the effects of Clostridium butyricum in the treatment of immunological disorder of patients with hepatic cirrhosis.Methods: Sixteen patients with cirrhosis took orally Clostridium butyricum 3g/d for three months.T lymphocyte subpopulation CD3,CD4,CD8 as well as NK cells in peripheral blood and serum levels of immunorglobulin(IgC, IgA, IgM) were detected before and after administration of Clostridium butyricum. Resuts: The levels of serum IgC and IgA decreased significantly after treatment with Clostridim butyricum. Conclusion: Treatment with Clostridium butyricum for cirrhosis may inhibit hannful intestinal bacteria and obviously decrease the antigens from intestine in systemic circulation, improve immunological abnormalities in patients with hepatic cirrhosis.